C-3PGUautologous cellular therapy, MSC-NTF cells, neurodegeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Brainstorm Cell Therapeutics autologous cellular therapy, MSC-NTF cells, neurodegeneration
BrainStorm Cell Therapeutics is a clinical-stage biotechnology company focused on autologous cellular therapeutics for highly debilitating neurodegenerative diseases. Its NurOwn technology platform is used for production of commercial-ready MSC-NTF cells. The company states that its autologous MSC-NTF cell therapy is investigational and not FDA approved.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Brainstorm Cell Therapeutics — Near-term readout · Lower middle. Derived deterministically from 4 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic